Tag: fy25

Ulta Beauty’s FY25 investments goals critical for growth — analysts (ULTA:NASDAQ)

Ulta Beauty's Q4 Results: A Testament to Long-Term Potential After dissecting Ulta Beauty's (NASDAQ: ULTA) fourth-quarter results, Wall Street analysts seem to agree: the company's...

Vivid Seats sees FY25 revenue $730M-$810M, consensus $801.56M

Vivid Seats' Financial Outlook for FY25: A Comprehensive Overview Introduction Vivid Seats, a leading marketplace for tickets to live events, has recently shared its financial projections...

Vivid Seats reports Q4 results; initiates FY25 outlook

Vivid Seats Q4 Results and FY25 Outlook: A Comprehensive Overview 1. Q4 Financial Highlights: A Stellar Performance Vivid Seats concluded 2024 on a high note with...

DexCom receives warning letter from FDA, sees no impact to FY25 guidance

Introduction In a recent regulatory filing, DexCom (DXCM) revealed that it received a warning letter from the U.S. Food and Drug Administration (FDA) on March...

Popular Articles